Лефлуномид в современной патогенетической терапии ревматических заболеваний
Мусина Флариса Сабирьяновна, П. Д. Болотов, Р. Т. Хамидуллин et al. · Медицинский вестник Башкортостана · 2013
The present study was conducted to determine effectiveness of leflunomide given for a long time to patients with psoriatic arthritis (PsA).A 6-month open study has been performed. We have examined 26 patients (mean age 43.7±11.2) with a disease history from 6months to 10 years. All studied patients gave written informed consent before any procedures were undertaken. Leflunomide was administered at a dose of 100 mg per day during the first three days followed by a dose of 20 mg per day.The use of leflunomide in PsA patients for 6 months significantly reduces FPS and FIS. According to PsARC and ACR50 crite-ria, leflunomide has shown high activity. Thus, recommendations for leflunomide therapy for PsA patients may be reasonable. High efficacy and good tolerance of leflunomide used for the management of PsA patients has been shown.
Cited by 0 works.